<DOC>
	<DOC>NCT00149942</DOC>
	<brief_summary>This open, single arm, explorative study aims to investigate the evolution of gastrointestinal adverse events after switch from MMF to EC-MPS in organ transplanted patients suffering from gastrointestinal adverse events while on MMF therapy.</brief_summary>
	<brief_title>Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) Therapy</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Kidney or liver transplanted patients Currently under MMF therapy and currently suffering from upper or lower gastrointestinal adverse events Recent graft rejection before the study Other preexisting conditions that may cause gastrointestinal complaints Use of other drugs known to cause gastrointestinal complaints Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Enteric coated mycophenolate sodium</keyword>
	<keyword>transplantation</keyword>
	<keyword>gastrointestinal adverse events</keyword>
	<keyword>Kidney and liver transplantation patients experiencing GI AEs with current MMF treatment</keyword>
</DOC>